Company Overview:
- A bulk drug manufacturer (established in 1993)
- focused on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries
- listed its shares in the Indian stock exchanges in 2016
- manufacturing facilities located in Maharashtra and Gujarat state
- four units for APIs/intermediates and one unit for formulation
The company is said to be one of India’s largest manufacturer of vitamin C, which is ascorbic acid, as well as its derivatives.
Clients:
Sun Pharmaceutical Ltd, Pfizer Ltd, Abbott Healthcare and Glaxosmithkline Pharmaceuticals are among its top clients for active pharmaceutical ingredients in the domestic market.
Recent Developments:
- Govt. of India has started an anti -dumping investigation into imports of vitamin C from China in the wake of the domestic manufacturers making a case for imposition of the levy.
- The company is said to complete the acquisition of “stressed assets” ( which includes factory, industrial land and vacant flats) for 61Cr. from Saraswat Cooperative Bank by October 2020.
Investor Presentation from BSE website for further reading:
2 posts - 1 participant